// App-Quantinova.ai

TPS5090 : Nivolumab and ipilimumab treatment in prostate cancerwith an immunogenic signature (NEPTUNES).

Researchers

Presenter

  • Yien Ning Sophia Wong

Principal Investigators

  • Debra Hannah Josephs

  • Robert J Jones

  • Simon J. Crabb

  • Sandy Beare

  • Marian Duggan

  • Laura White

  • Nikolaos Charlaftis

  • Graham Wheeler

  • Josep Linares

  • Sergio A. Quezada

  • Leah Ensell

  • Cliona Flanagan

  • Bihani Yoshana Kularatne

  • Moon Chung

  • Colin C. Pritchard

  • Alex Freeman

  • Teresa Marafioti

  • Mark David Linch

Medical Centers

  • Cancer Immunology Unit, University College London Cancer Institute, London, United Kingdom

  • Portsmouth Hospital NHS Trust, Portsmouth, United Kingdom

  • Guy's Hospital, London, United Kingdom

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom

  • Department of Medical Oncology, University College London Hospital, London, United Kingdom

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • University of Washington, Seattle, WA

  • Kings College London, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • tumor-infiltrating lymphocytes

  • Tumor mutational burden

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • II

Study Id's

  • NCT03061539

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved